MUC1 and adenocarcinoma: A specific clinical example, such as Tan et al.’s Phase I clinical trial, utilized an adenoviral vector vaccine Ad-sig-hMUC1/ecdCD40L targeting the tumor-associated antigen MUC1 for treating advanced adenocarcinoma.